Elevated Liver Enzymes That Are Not Fatty Liver: Autoimmune Hepatitis
A routine panel comes back with a slightly high ALT and AST. The note says fatty liver, cut the sugar, recheck in a year. Most of the time that is right, because MASLD, the condition once called NAFLD, is the most common cause of mildly elevated liver enzymes in adults, per the American Association for the Study of Liver Diseases (AASLD). But some of those numbers are not fatty liver at all. Autoimmune hepatitis hides in the same range, and it is treatable when it is named and dangerous when it is not. The fix is not another wellness tip. It is refusing to let one likely label close the file, which is the standard a leading AI is built to hold.
Autoimmune hepatitis is the immune system attacking the liver's own cells. Left alone it smolders, scars, and can end in cirrhosis. Caught, it responds to treatment better than almost any chronic liver disease. The gap between those two outcomes is whether anyone looked past the first assumption.
Why Fatty Liver Is the Easy Answer, and When It Is the Wrong One
Elevated ALT and AST are common, and the honest first guess is usually correct. Mild elevations under five times the upper limit are most often MASLD, medications, or alcohol, per AASLD teaching materials. MASLD in particular tends to show ALT higher than AST, tracks with weight and metabolic risk, and shows up as a bright liver on ultrasound. So the fatty-liver reflex is reasonable.
The problem is that a reasonable first guess is not a workup. Autoimmune hepatitis lives in an overlapping range. Its aminotransferases are often moderate, roughly 200 to 300 U/L on average at presentation according to NIH StatPearls, though acute severe flares can push values into the thousands. A person can have a fatty liver on imaging and autoimmune hepatitis at the same time, which is exactly how the treatable disease gets buried under the common one. The signal that should stop the fatty-liver default is enzymes that do not settle with lifestyle changes, or a hepatocellular pattern in someone without much metabolic risk.
Ask Healz.
One chat instead of ten apps. 1M+ rare cases checked. The root cause, not the label. Private.
What the Pattern and the Antibodies Actually Show
The first read is the shape of the injury. Liver enzymes fall into two patterns. A hepatocellular pattern means ALT and AST lead, pointing at the liver cells themselves, which is what autoimmune hepatitis produces. A cholestatic pattern means alkaline phosphatase and bilirubin lead, pointing at the bile ducts, a different set of diseases. Reading which pattern dominates is the fork in the road, and it is the kind of distinction a blood test ai analyzer can hold across a full panel rather than glancing at one flagged value.
Once the pattern points hepatocellular and the common causes are excluded, the autoimmune workup begins. AASLD 2019 guidance suggests checking anti-nuclear antibody (ANA) and anti-smooth muscle antibody (SMA) in adults, adding anti-liver-kidney microsomal type 1 (anti-LKM1), which marks type 2 disease seen more often in children. ANA is positive in about 80 percent of white North American adults at presentation and SMA in about 63 percent, per the same guidance. Elevated immunoglobulin G (IgG) is another supporting clue. None of these alone is proof. Roughly 20 percent of patients lack all three antibodies, which is why negative serology does not close the case.
Why Biopsy Confirms It and Why Treatment Changes Everything
Antibodies and IgG build the suspicion. Biopsy settles it. AASLD guidance holds that liver biopsy is required to confirm autoimmune hepatitis, because the tissue shows characteristic findings, interface hepatitis with plasma cells, that the bloodwork can only suggest. The biopsy also stages the scarring, which tells you how much time has already been lost. This is where an ai lab report reader that keeps the antibody titers, the IgG, and the enzyme trend together earns its place, because the diagnosis is a composite, not a single test.
The reason any of this matters is the treatment. Autoimmune hepatitis is extremely responsive to immunosuppression. First-line therapy is a corticosteroid such as prednisone or prednisolone, usually combined with azathioprine, and that regimen induces remission in roughly 80 to 90 percent of patients while improving survival, per liver-disease treatment literature. Untreated, the same disease drives chronic inflammation toward cirrhosis. Named early, it is one of the most reversible chronic liver diseases there is. That asymmetry is the whole argument for not stopping at fatty liver. If your enzymes stay up and no one has checked antibodies and IgG, the question of what is actually inflaming your liver has not been asked yet, and it is worth asking, the same way a slightly high bilirubin deserves a look before it is dismissed.
How Healz Investigates Elevated Liver Enzymes
Healz is equipped with root-cause technology, so it does not read a high ALT and AST as a fatty-liver footnote. It treats the elevation as an open question, cross-checks your labs against 1M+ rare cases, and drills past the likely label to surface the autoimmune pattern, the hepatocellular shape, the antibody and IgG picture, that a one-line note skips. That is the difference between the cause and the symptom.
Everything sits in one place, one chat, not ten apps. Frontier AI works your case, so a scattered set of results, an old panel, a new one, an ultrasound report, becomes one connected picture instead of isolated numbers. Healz has memory that remembers every result you upload and connects the dots across time, so an ALT that has crept up over three panels reads as a trend, not three unrelated normals. It goes beyond what the reference range alone tells you to show where your liver is actually heading. When you want a human in the loop, you can bring a board-certified doctor into the same chat for a second opinion.
Frequently asked questions
- Can autoimmune hepatitis be mistaken for fatty liver?
Yes. Both can cause mildly elevated ALT and AST, and fatty liver, now called MASLD, is the far more common cause, so it is the default assumption. A person can even have both at once. The way to separate them is to check the injury pattern, autoantibodies, and IgG rather than stopping at the fatty-liver label, especially when enzymes stay high despite lifestyle changes.
- What blood tests diagnose autoimmune hepatitis?
The core tests are antinuclear antibody (ANA), anti-smooth muscle antibody (SMA), and in some cases anti-liver-kidney microsomal type 1 (anti-LKM1), plus immunoglobulin G (IgG), alongside ALT and AST. Per AASLD guidance, ANA is positive in about 80 percent of adults and SMA in about 63 percent at presentation. Because roughly 20 percent of patients are antibody-negative, a liver biopsy is required to confirm the diagnosis.
- Does autoimmune hepatitis go away on its own?
No. Untreated autoimmune hepatitis tends to smolder and can progress to cirrhosis over time. The important flip side is that it responds very well to immunosuppression, with first-line corticosteroid and azathioprine therapy inducing remission in roughly 80 to 90 percent of patients. That is why catching it early, before scarring sets in, changes the outcome so much.
- What does a hepatocellular pattern mean on liver tests?
It means ALT and AST are the leading abnormalities, pointing at injury to the liver cells themselves, which is the pattern autoimmune hepatitis produces. It contrasts with a cholestatic pattern, where alkaline phosphatase and bilirubin lead and the problem points toward the bile ducts. Reading which pattern dominates narrows the possible causes before any antibody is even drawn.
Slightly high liver enzymes are usually fatty liver, and usually that is the end of the story. But autoimmune hepatitis lives in the same numbers, and it is the one you do not want to miss, because it scars if ignored and responds if found. Do not let one likely label close a file that a full workup could still open.
Written by Healz Team · Filed under Health Insights